期刊文献+

四环素诱导的丙型肝炎病毒非结构蛋白5B稳定细胞株的构建和检测

Establishment and detection of a tetracycline-inducible stable cell line expressing hepatitis C virus nonstructural protein 5B
下载PDF
导出
摘要 丙型肝炎病毒(HCV)感染个体后在宿主细胞内长时间保持低水平复制,与慢性肝炎、肝硬化及肝细胞肝癌的发生密切相关。目前,HCV感染后肝细胞发生转化的具体机制还不清楚。非结构蛋白5B(NS5B)是HCV编码的非结构蛋白之一,具有RNA依赖的RNA聚合酶活性(RdRp),是病毒复制所需的关键酶。除参与病毒复制外,NS5B通过直接与宿主蛋白相互作用影响细胞的正常功能逐渐成为人们关注的焦点。为深入了解NS5B在病毒复制和致病过程中的作用,本研究在肝癌细胞系HepG2细胞中构建了可由四环素诱导(Tet-On)的NS5B稳定细胞株。结果显示,与对照组相比,加入四环素可成功诱导NS5B。加入不同浓度的四环素或经过不同的诱导时间,目的蛋白均能同时被标签抗体和抗NS5B抗体检测。免疫荧光法进一步证实NS5B存在于细胞质内。本研究所构建的NS5B稳定细胞株可用于诸多后续试验,为深入研究NS5B的功能提供了细胞模型。 Hepatitis C virus(HCV) infection is a major risk factor of chronic hepatitis,liver cirrhosis,and hepatocellular carcinoma(HCC).However,the detailed mechanism of action on cancer caused by HCV is still elusive.Nonstructural protein 5B(NS5B) is one of the nonstructural proteins encoded by HCV and is essential for HCV RNA replication due to its RNA-dependent RNA polymerase(RdRp) activity.In addition to participating in viral RNA replication,NS5B was also found to be involved in the pathogenicity of HCV through a direct interaction with host proteins.In order to address the role of NS5B in HCV replication and pathogenicity,we constructed a tetracycline-inducible(Tet-On) stable cell line expressing NS5B in HepG2 cells.Protein expression was examined by Western blot using both tag antibody and anti-NS5B antibody induced by doxycycline either at different concentrations or at different indicated time points.Moreover,immunofluorescence assay further confirmed the results.In conclusion,the HepG2 Tet-On NS5B stable cell line may be a useful model to investigate the role of NS5B in HCV replication and pathogenicity.
出处 《微生物与感染》 2011年第2期84-89,共6页 Journal of Microbes and Infections
基金 "十一五"国家科技重大专项(2008ZX10203)
关键词 丙型肝炎病毒 非结构蛋白5B HEPG2 TET-ON Hepatitis C virus Nonstructural protein 5B HepG2 Tet-On
  • 相关文献

参考文献22

  • 1Hoofnagle J H. Course and outcome of hepatitis C [J]. Hepatology, 2002, 36(5 Suppl 1).:S21-S29.
  • 2Yang JD, Roberts LR. Hepatocellular carcinoma: A global view [J]. Nat Rev Gastroenterol Hepatol, 2010, 7(8) : 448- 458.
  • 3Shimakami T, Lanford RE, Lemon SM. Hepatitis C, recent successes and continuing challenges in the development of improved treatment modalities [J]. Curr Opin Pharmacol, 2009, 9(5): 537-544.
  • 4Ascione A, de Luca M, Tartaglione MT, Lampasi F, di Costanzo GG, Lanza AG, Picciotto FP, Marino-Marsilia G, Fontanella L, Leandro G. Peginterferon alfa-2a plus ribavirin is more effective than peginterferon alfa-2b plus ribavirin for treating chronic hepatitis C virus infection [J]. Gastroenterology, 2010, 138(1): 116-122.
  • 5Feld JJ, Hoofnagle JH. Mechanism of action of interferon and ribavirin in treatment of hepatitis C [J]. Nature, 2005, 436(7053) : 967-972.
  • 6Lohmann V, Korner F, Herian U, Bartenschlager R. Biochemical properties of hepatitis C virus NSSB RNA dependent RNA polymerase and identification of amino acid sequence motifs essential for enzymatic activity [J].J Virol, 1997, 71(11): 8416-8428.
  • 7Jonckers TH, Lin TI, Buyck C, Lachau-Durand S, Vandyck K, van Hoof S, Vandekerckhove LA, Hu L, Berke JM, Vijgen L, Dillen LL, Cummings MD, de Kock H, Nilsson M, Sund C, Rydegard C, Samuelsson B, Rosenquist A, Funning G, van Emelen K, Simmen K, Raboisson P. 2'-Deoxy-2'-spirocyclopropylcytidine revisited :a new and selective inhibitor of the hepatitis C virus NS5B polymerase [J]. J Mcd Chem, 2010, 53(22): 8150-8160.
  • 8Vermehren J, Sarrazin C. New HCV therapies on the horizon [J]. Clin Microbiol Infect, 2011, 17(2): 122-134. doi: 10.1111/j. 1469-0691. 2010. 03430. x.
  • 9Waiters KA, Syder AJ, Lederer SL, Diamond DL, Paeper B, Rice CM, Katze MG. Genomic analysis reveals a potential role for cell cycle perturbation in HCV-mediated apoptosis of cultured hepatocytes [J]. PLoS Pathog, 2009, 5(1): e1000269.
  • 10Gao L, Aizaki H, He JW, Lai MM. Interactions betweenviral nonstructural proteins and host protein hVAP-33 mediate the formation of hepatitis C virus RNA replication complex on lipid raft[J]. J Virol, 2004, 78(7):3480-3488.

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部